[A25-94] Garadacimab (hereditary angioedema) – Addendum to Project A25-41
Last updated 21.08.2025
Project no.:
A25-94
Commission:
Commission awarded on 08.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
For routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older
Unchanged after addendum: hint of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-94
| Project no. | Title | Status |
|---|---|---|
| A25-41 | Garadacimab (hereditary angioedema) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-08-21 A G-BA decision was published.